Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Key Takeaway: Enanta Pharmaceuticals is set to present data on Zelicapavir, an oral, once-daily N-Protein inhibitor aimed at treating Respiratory Syncytial Virus (RSV). This presentation will take place at the ESCMID Global 2026 event. The focus on RSV treatment highlights the ongoing research in antiviral therapies.